BridgeBio Pharma BBIO Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total current assets?
- BridgeBio Pharma (BBIO) reported total current assets of $1.24B in Q1 2026.
- How has BridgeBio Pharma's total current assets changed year-over-year?
- BridgeBio Pharma's total current assets increased by 78.6% year-over-year, from $695.17M to $1.24B.
- What is the long-term trend for BridgeBio Pharma's total current assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total current assets has grown at a 4.4% compound annual growth rate (CAGR), from $642.82M to $797.75M.
- What does total current assets mean?
- The sum of all assets the company expects to turn into cash within one year.
- How do you interpret total current assets?
- A higher total indicates stronger short-term liquidity and a greater buffer against unexpected financial obligations.
- How does total current assets compare across companies?
- Standard metric for assessing liquidity across all industries; essential for evaluating solvency.